Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 1/2014

01.02.2014 | Review Article

Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer

verfasst von: Lorena Rocha Ayres, André de Oliveira Baldoni, Anna Paula de Sá Borges, Leonardo Régis Leira Pereira

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background Oral treatment in women with breast cancer has been increasingly used. However, a potentially negative side of oral medication is poor patient adherence and/or discontinuation, which reduces the treatment effectiveness, accelerating progression of the disease and reducing the patient survival rate. Aim of the review To compare the rates of adherence and/or discontinuation and the methodologies used to assess these outcomes. It was conducted an integrative review of original articles published from 2000 to 2012, in which their primary outcome was to quantify medication adherence and/or discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Methods Original studies were searched in the PubMed/MEDLINE, Scopus, Embase and SciELO databases. The Medical Subject Heading was used to define descriptors. The descriptor “breast neoplasms” was used in all combinations. Each of the descriptors “medication adherence” and “patient compliance” were combined with each of the following descriptors “tamoxifen”, “aromatase inhibitors”, “selective estrogen receptor modulators”, or the terms “letrozole”, “anastrozole”, and “exemestane”. Results Twenty-four original articles were included. Our study showed a wide range of adherence and discontinuation rates, ranging from 45–95.7 and 12–73 %, respectively. Regarding the methodological development of the selected articles, a high prevalence (87.5 %) of prospective and/or retrospective longitudinal studies was found. In addition, there was a high prevalence of studies using a database (70.8 %). Among some of the studies, it was shown that patient adherence to hormonal therapy gradually reduces, while discontinuation increases during the treatment. Conclusions It was observed a great diversity among rates of adherence and/or discontinuation of hormonal therapy for breast cancer, which may be due to a lack of methodology standardization. Therefore, adequate and validated methods to ensure reliability of the results and allow comparison in the literature are needed. Furthermore, adherence decreases and discontinuation increases over time, suggesting the need for patient continuous education and a pharmacotherapeutic follow up by health professionals to improve these clinical outcomes.
Literatur
1.
Zurück zum Zitat Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33(5):315–8.PubMedCrossRef Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33(5):315–8.PubMedCrossRef
2.
Zurück zum Zitat Montazeri A, Vahdaninia M, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer. 2008;8:330.PubMedCentralPubMedCrossRef Montazeri A, Vahdaninia M, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer. 2008;8:330.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Miaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs. 2008;12(2):213–21.PubMedCrossRef Miaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs. 2008;12(2):213–21.PubMedCrossRef
4.
Zurück zum Zitat Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010;81(11):1339–46.PubMed Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010;81(11):1339–46.PubMed
5.
Zurück zum Zitat Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652–61.PubMedCrossRef Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652–61.PubMedCrossRef
6.
Zurück zum Zitat Early breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet. 2005;365(2):1687–717. Early breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet. 2005;365(2):1687–717.
7.
Zurück zum Zitat Crivellari D, Sun Z, Coates AS, Price KN, Thurlimann B, Mouridsen H, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008;26(12):1972–9.PubMedCrossRef Crivellari D, Sun Z, Coates AS, Price KN, Thurlimann B, Mouridsen H, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008;26(12):1972–9.PubMedCrossRef
8.
Zurück zum Zitat Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.PubMedCrossRef Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.PubMedCrossRef
9.
Zurück zum Zitat Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011;125(1):279–87.PubMedCrossRef Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011;125(1):279–87.PubMedCrossRef
10.
Zurück zum Zitat Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use side effects, and discontinuation in older women. J Clin Oncol. 2001;19(2):322–8.PubMed Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use side effects, and discontinuation in older women. J Clin Oncol. 2001;19(2):322–8.PubMed
11.
Zurück zum Zitat Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97–102.PubMedCrossRef Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97–102.PubMedCrossRef
12.
Zurück zum Zitat Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–20.PubMedCrossRef Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–20.PubMedCrossRef
13.
Zurück zum Zitat Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7(6 Suppl):5–9.PubMedCrossRef Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7(6 Suppl):5–9.PubMedCrossRef
14.
Zurück zum Zitat Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Principles of Internal Medicine. 2006;1: 16th edn. ISBN 85-86804-54-1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Principles of Internal Medicine. 2006;1: 16th edn. ISBN 85-86804-54-1.
15.
Zurück zum Zitat Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62.PubMedCrossRef Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62.PubMedCrossRef
16.
Zurück zum Zitat Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor–positive breast cancer. J Clin Oncol. 2008;26(4):549–55.PubMedCrossRef Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor–positive breast cancer. J Clin Oncol. 2008;26(4):549–55.PubMedCrossRef
17.
Zurück zum Zitat Font R, Espinas JA, Gil–Gil M, Barnadas A, Ojeda B, Tusquets I, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer. 2012;107(8):1249–56.PubMedCentralPubMedCrossRef Font R, Espinas JA, Gil–Gil M, Barnadas A, Ojeda B, Tusquets I, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer. 2012;107(8):1249–56.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48(13):1939–46.PubMedCrossRef Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48(13):1939–46.PubMedCrossRef
19.
Zurück zum Zitat Gotay C, Dunn J. Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):709–15.PubMedCrossRef Gotay C, Dunn J. Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):709–15.PubMedCrossRef
21.
Zurück zum Zitat Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546–53.PubMedCrossRef Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546–53.PubMedCrossRef
22.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMedCrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMedCrossRef
23.
Zurück zum Zitat Organization World Health. Adherence to long-term therapies. Evidence for action. Geneva: WHO; 2003 ISBN 92 4 154599 2. Organization World Health. Adherence to long-term therapies. Evidence for action. Geneva: WHO; 2003 ISBN 92 4 154599 2.
24.
Zurück zum Zitat Bugalho A, Carneiro, AV. Intervenções para aumentar a adesão terapêutica em patologias crónicas. Lisboa: Faculdade de Medicina de Lisboa, 2004 [Interventions to enhance medication adherence in chronic conditions. Lisbon: Faculty of Medicine of Lisbon, 2004]. ISSN 1074-308. Bugalho A, Carneiro, AV. Intervenções para aumentar a adesão terapêutica em patologias crónicas. Lisboa: Faculdade de Medicina de Lisboa, 2004 [Interventions to enhance medication adherence in chronic conditions. Lisbon: Faculty of Medicine of Lisbon, 2004]. ISSN 1074-308.
25.
Zurück zum Zitat Kardas P, Morrison V, Fargher E, Parveens S, Plumpton C, Clyne W, et al. Report on the determinants of patients non-adherence with short-term therapies and long-term treatments. Chapter 3: determinants of patients non-adherence. ABC Project: Ascertaining Barriers for Compliance, 2012. Kardas P, Morrison V, Fargher E, Parveens S, Plumpton C, Clyne W, et al. Report on the determinants of patients non-adherence with short-term therapies and long-term treatments. Chapter 3: determinants of patients non-adherence. ABC Project: Ascertaining Barriers for Compliance, 2012.
26.
Zurück zum Zitat Vrijens B, De Geest S, Hughes D, Kardas P, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.PubMedCrossRef Vrijens B, De Geest S, Hughes D, Kardas P, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.PubMedCrossRef
27.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG. PRSIMA Group (2009) Preferred reporting items for systematic reviews and meta- analyses: the PRISMA statement. J Clin Epidemiol. 2012;62(10):1006–12.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. PRSIMA Group (2009) Preferred reporting items for systematic reviews and meta- analyses: the PRISMA statement. J Clin Epidemiol. 2012;62(10):1006–12.CrossRef
28.
Zurück zum Zitat Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133(1):367–73.PubMedCrossRef Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133(1):367–73.PubMedCrossRef
29.
Zurück zum Zitat Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23(4):882–90.PubMedCrossRef Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23(4):882–90.PubMedCrossRef
30.
Zurück zum Zitat Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.PubMedCentralPubMedCrossRef Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer. 2011;104(10):1558–63.PubMedCentralPubMedCrossRef Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer. 2011;104(10):1558–63.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011;130(2):81–9.CrossRef Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011;130(2):81–9.CrossRef
33.
Zurück zum Zitat Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534–42.PubMedCrossRef Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534–42.PubMedCrossRef
34.
Zurück zum Zitat Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125(1):191–200.PubMedCrossRef Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125(1):191–200.PubMedCrossRef
35.
Zurück zum Zitat Dezentjé VO, Van Blijderveen NJ, Gelderblom H, Putter H, Van Herk-Sukel MP, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28(14):423–9.CrossRef Dezentjé VO, Van Blijderveen NJ, Gelderblom H, Putter H, Van Herk-Sukel MP, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28(14):423–9.CrossRef
36.
Zurück zum Zitat Van Herk-Sukel MP, Van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843–51.PubMedCrossRef Van Herk-Sukel MP, Van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843–51.PubMedCrossRef
37.
Zurück zum Zitat Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27(21):3445–51.PubMedCrossRef Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27(21):3445–51.PubMedCrossRef
38.
Zurück zum Zitat Ma AM, Barone J, Wallis AE, Wu NJ, Garcia LB, Estabrook A, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg. 2008;196(4):500–4.PubMedCrossRef Ma AM, Barone J, Wallis AE, Wu NJ, Garcia LB, Estabrook A, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg. 2008;196(4):500–4.PubMedCrossRef
39.
Zurück zum Zitat Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832–9.PubMedCrossRef Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832–9.PubMedCrossRef
40.
Zurück zum Zitat Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431–9.PubMedCrossRef Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431–9.PubMedCrossRef
41.
Zurück zum Zitat Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42(14):2271–6.PubMedCrossRef Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42(14):2271–6.PubMedCrossRef
42.
Zurück zum Zitat Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22(16):3309–15.PubMedCrossRef Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22(16):3309–15.PubMedCrossRef
43.
Zurück zum Zitat Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–6.PubMedCrossRef Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–6.PubMedCrossRef
44.
Zurück zum Zitat Waterhouse DM, Calzone KA, Mele C, Brener DE. Adherence to oral tamoxifen non-compliance: a comparation of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–97.PubMed Waterhouse DM, Calzone KA, Mele C, Brener DE. Adherence to oral tamoxifen non-compliance: a comparation of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–97.PubMed
45.
46.
Zurück zum Zitat Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin Breast Cancer. 2003;4(Suppl 1):S42–8.PubMedCrossRef Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin Breast Cancer. 2003;4(Suppl 1):S42–8.PubMedCrossRef
47.
Zurück zum Zitat Kaplow R. Innovations in antineoplastic therapy. Nurs Clin N Am. 2005;40(1):77–94.CrossRef Kaplow R. Innovations in antineoplastic therapy. Nurs Clin N Am. 2005;40(1):77–94.CrossRef
48.
Zurück zum Zitat Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol Nurs. 2010;14(1):41–7.PubMedCrossRef Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol Nurs. 2010;14(1):41–7.PubMedCrossRef
49.
Zurück zum Zitat Obreli-Neto PR, Baldoni AO, Guidoni CM, Bergamini D, Hernandes KC, da Luz RT, et al. Métodos de avaliação de adesão à farmacoterapia [Methods for estimating adherence to the pharmacotherapy]. Rev Bras Farm. 2012;93(4):403–10. Obreli-Neto PR, Baldoni AO, Guidoni CM, Bergamini D, Hernandes KC, da Luz RT, et al. Métodos de avaliação de adesão à farmacoterapia [Methods for estimating adherence to the pharmacotherapy]. Rev Bras Farm. 2012;93(4):403–10.
50.
Zurück zum Zitat Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37.PubMedCrossRef Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37.PubMedCrossRef
51.
Zurück zum Zitat Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, LoCasale R. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2012;21(1):1–10.PubMedCrossRef Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, LoCasale R. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2012;21(1):1–10.PubMedCrossRef
52.
Zurück zum Zitat Gold DT. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119(4 Suppl 1):S32–7.PubMedCrossRef Gold DT. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119(4 Suppl 1):S32–7.PubMedCrossRef
53.
Zurück zum Zitat Clyne W, Mshelia C, McLachlan S, Clyne W, Geest S, Ruppar T, et al. Exploring the current practices of adherence management by healthcare professionals and the pharmaceutical industry. Chapter 5: determinants of patients non-adherence. ABC Project: Ascertaining Barriers for Compliance, 2012. Clyne W, Mshelia C, McLachlan S, Clyne W, Geest S, Ruppar T, et al. Exploring the current practices of adherence management by healthcare professionals and the pharmaceutical industry. Chapter 5: determinants of patients non-adherence. ABC Project: Ascertaining Barriers for Compliance, 2012.
54.
Zurück zum Zitat Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. Pharmacotherapy. 2004;24(11):1491–8.PubMedCrossRef Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. Pharmacotherapy. 2004;24(11):1491–8.PubMedCrossRef
55.
Zurück zum Zitat Borges APS, Guidoni CM, Ferreira LD, Freitas O, Pereira LRL. The pharmaceutical care of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32(6):730–6.PubMedCrossRef Borges APS, Guidoni CM, Ferreira LD, Freitas O, Pereira LRL. The pharmaceutical care of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32(6):730–6.PubMedCrossRef
56.
Zurück zum Zitat Obreli-Neto PR, Guidoni CM, Baldoni AO, Pilger D, Cruciol-Souza JM, Gaeti-Franco WP, et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm. 2011;33(4):642–9.PubMedCrossRef Obreli-Neto PR, Guidoni CM, Baldoni AO, Pilger D, Cruciol-Souza JM, Gaeti-Franco WP, et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm. 2011;33(4):642–9.PubMedCrossRef
57.
Zurück zum Zitat Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011;17(3):213–23.PubMed Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011;17(3):213–23.PubMed
58.
Zurück zum Zitat Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer. 2012;20(11):2669–77.PubMedCentralPubMedCrossRef Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer. 2012;20(11):2669–77.PubMedCentralPubMedCrossRef
Metadaten
Titel
Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer
verfasst von
Lorena Rocha Ayres
André de Oliveira Baldoni
Anna Paula de Sá Borges
Leonardo Régis Leira Pereira
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 1/2014
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9833-5

Weitere Artikel der Ausgabe 1/2014

International Journal of Clinical Pharmacy 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.